Study of benmelstobart plus chemo-radiation before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an immunotherapy drug (benmelstobart) to standard chemotherapy and radiation before surgery can help treat a certain type of esophageal cancer that can be surgically removed. The goal is to see if this combination is safe and works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of esophageal cancer called squamous cell carcinoma that can be surgically removed and has not spread beyond the chest area (stages T1-3N+M0 or T3NanyM0).
- You have not had any prior treatment for your esophageal cancer, such as chemotherapy, radiation, or immunotherapy.
- You are in generally good health with a performance status of 0 or 1 (able to carry out daily activities without help).
- Your blood counts, liver, kidney, and thyroid function are within acceptable ranges as determined by lab tests.
- If you are able to become pregnant or father a child, you agree to use effective contraception during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This study tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (sintilimab) given before surgery for esophageal cancer. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.